Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
Denali Therapeutics Inc. (NASDAQ:DNLI) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, focused on developing therapies for neurodegenerative and lysosomal storage disorders. Its proprietary TransportVehicle (TV) technology enables the delivery of biologics across the blood-brain barrier, targeting neurological symptoms often left untreated by conventional therapies.
In July 2025, the company achieved a major milestone as the FDA accepted and granted Priority Review for its Biologics License Application (BLA) for tividenofusp alfa, a novel enzyme replacement therapy for Hunter syndrome (MPS II). This designation highlights the urgent medical need and sets a PDUFA decision date of January 5, 2026, opening the door for potential approval and launch by early 2026.
Tividenofusp alfa is a first-in-class brain-penetrant enzyme therapy designed to overcome a key limitation of current treatments, which do not reach the brain and fail to address neurological symptoms. In clinical trials, Denali Therapeutics Inc. (NASDAQ:DNLI)'s therapy demonstrated effective delivery of the missing enzyme to the central nervous system, showing promise for addressing both somatic and neurological aspects of Hunter syndrome.
A scientist in a labcoat inspecting a microscope focusing on a microorganism related to the biopharmaceutical company's therapies.
If approved, this therapy would not only offer new hope for patients with Hunter syndrome but also validate the corporation's TV platform, accelerating the development of additional treatments for other disorders like Sanfilippo syndrome (DNL126) and other central nervous system diseases. The milestone marks a transformative moment for Denali Therapeutics Inc. (NASDAQ:DNLI), potentially expanding its leadership in next-generation rare disease therapies.
While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Over 64,000 pounds of butter recalled over allergen concerns
A voluntary recall has been issued for over 64,000 pounds of butter found to contain an undeclared allergen. The voluntary recall was initiated July 14 by food ingredient company Bunge North America, affecting 1,800 cases of its NH European Style Butter Blend which did not declare milk as an allergen on the label. As of July 30, the Food and Drug Administration (FDA) labeled it a Class II recall, the second-highest risk level. A Class II recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. The butter was sent to 12 distribution centers located throughout the U.S., as well as a single distribution center located in the Dominican Republic. Affected cases were packaged in white paperboard and contained 36 blocks. Affected cases of butter contain the following identification information: Product code: 5023937 UPC: 1 00 78684 73961 2 Lot code: 5064036503 The butter recall is the latest in a string of food-and-drink-related issues across the U.S. Earlier this week, High Noon Hard Seltzers were recalled over a labeling error. Some cans, filled with High Noon Vodka Seltzer, were mislabeled as the non-alcoholic Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition. As a result, drinking the beverage in these cans can result in unintentional alcohol consumption. However, no illnesses or adverse events have been reported to date. Two lots of the High Noon Beach Variety 12-packs were affected, according to a press release. High Noon initiated the recall after it discovered 'a shared packaging supplier mistakenly shipped empty Celsius cans to High Noon,' according to the press release. The recalled High Noon Beach Variety 12-packs were sent to distributors in eight states who then shipped the product to retailers in six states — Florida, New York, Ohio, South Carolina, Virginia, and Wisconsin — between July 21 and 23. Even if they didn't purchase the High Noon packs, consumers are encouraged to ensure that their Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition, does not have the same lot codes as the recalled cans. Single-serve coffee pods have also been recalled this week. New Mexico Piñon Coffee announced in a press release that it was voluntarily recalling 154 boxes of its Dark Pinon Single Serve Cups, which have 10 pods per box. The recall was issued because of the 'potential introduction of food coloring into the cups,' which are compatible with Keurig machines, during brewing. The recalled coffee pods were sold at popular retailers nationwide, including Target, Costco, Walmart, and Kroger. Although there weren't any reports of illness or injury, consumers are urged to throw affected pods away or return them to the place of purchase.
Yahoo
7 minutes ago
- Yahoo
Earnings To Watch: Assurant (AIZ) Reports Q2 Results Tomorrow
Insurance services company Assurant (NYSE:AIZ) will be reporting results this Tuesday afternoon. Here's what investors should know. Assurant met analysts' revenue expectations last quarter, reporting revenues of $3.07 billion, up 6.7% year on year. It was a strong quarter for the company, with a solid beat of analysts' EPS estimates and an impressive beat of analysts' net premiums earned estimates. Is Assurant a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Assurant's revenue to grow 6.5% year on year to $3.11 billion, in line with the 7.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.45 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Assurant has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 2% on average. Looking at Assurant's peers in the property & casualty insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Mercury General delivered year-on-year revenue growth of 13.2%, beating analysts' expectations by 2%, and Allstate reported revenues up 6%, falling short of estimates by 0.7%. Mercury General's stock price was unchanged after the resultswhile Allstate was up 5.7%. Read our full analysis of Mercury General's results here and Allstate's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the property & casualty insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4% on average over the last month. Assurant is down 2.6% during the same time and is heading into earnings with an average analyst price target of $233.20 (compared to the current share price of $186.48). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Grocery Outlet (GO) Q2 Earnings: What To Expect
Discount grocery store chain Grocery Outlet (NASDAQ:GO) will be reporting results this Tuesday after the bell. Here's what investors should know. Grocery Outlet met analysts' revenue expectations last quarter, reporting revenues of $1.13 billion, up 8.5% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates. Is Grocery Outlet a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Grocery Outlet's revenue to grow 5.2% year on year to $1.19 billion, slowing from the 11.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.17 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Grocery Outlet has missed Wall Street's revenue estimates twice over the last two years. Looking at Grocery Outlet's peers in the non-discretionary retail segment, only Sprouts has reported results so far. It beat analysts' revenue estimates by 2.3%, delivering year-on-year sales growth of 17.3%. The stock was down 4.1% on the results. Read our full analysis of Sprouts's earnings results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the non-discretionary retail stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.1% on average over the last month. Grocery Outlet is up 4.2% during the same time and is heading into earnings with an average analyst price target of $15.62 (compared to the current share price of $13.80). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
